ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among
NSCLC
UBL
atezolizumab
biomarker
immune checkpoint inhibitors
Journal
Frontiers in genetics
ISSN: 1664-8021
Titre abrégé: Front Genet
Pays: Switzerland
ID NLM: 101560621
Informations de publication
Date de publication:
2021
2021
Historique:
received:
11
06
2021
accepted:
09
08
2021
entrez:
24
9
2021
pubmed:
25
9
2021
medline:
25
9
2021
Statut:
epublish
Résumé
Atezolizumab, an immune checkpoint inhibitor, has been approved for use in clinical practice in non-small cell lung cancer (NSCLC) patients, but potential biomarkers for response stratification still need further screening. In the present study, a total of 399 patients with high-quality ctDNA profiling results were included. The mutation status of ubiquitin-like conjugation (UBL) biological process genes (including
Identifiants
pubmed: 34557222
doi: 10.3389/fgene.2021.723670
pmc: PMC8452871
doi:
Types de publication
Journal Article
Langues
eng
Pagination
723670Informations de copyright
Copyright © 2021 Lu, Zhang, Lou, Yan, Zou, Hu, Wang, Chen, Yang, Wang, Zhang and Han.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Oncol. 2019 Sep 11;9:886
pubmed: 31572680
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
N Engl J Med. 2017 Jun 1;376(22):2109-2121
pubmed: 28445112
Ann Oncol. 2021 May;32(5):661-672
pubmed: 33736924
Acta Pharmacol Sin. 2020 Oct;41(10):1357-1365
pubmed: 32415222
Oncoimmunology. 2020 Feb 20;9(1):1731072
pubmed: 32158623
Cell Death Dis. 2021 Feb 10;12(2):170
pubmed: 33568630
JAMA Oncol. 2020 Dec 1;6(12):1952-1956
pubmed: 33119034
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Appl Immunohistochem Mol Morphol. 2018 Feb;26(2):e15-e21
pubmed: 28877075
J Biomed Biotechnol. 2011;2011:583929
pubmed: 21331359
Clin Cancer Res. 2020 Aug 15;26(16):4186-4197
pubmed: 32354698
Eur Respir J. 2019 Mar 7;53(3):
pubmed: 30578392
Cancer Biol Med. 2021 Mar 12;:
pubmed: 33710815
BMJ. 2019 Oct 7;367:l5460
pubmed: 31591158
Cancer Cell. 2020 Jan 13;37(1):8-19
pubmed: 31935374
N Engl J Med. 2020 Nov 19;383(21):2018-2029
pubmed: 33207094
J Natl Compr Canc Netw. 2021 Mar 02;19(3):254-266
pubmed: 33668021
Cell. 2018 Apr 5;173(2):371-385.e18
pubmed: 29625053
Cancer Cell. 2020 Sep 14;38(3):326-333
pubmed: 32750319
World J Clin Oncol. 2020 May 24;11(5):250-259
pubmed: 32728528
J Surg Res. 2018 Oct;230:181-185
pubmed: 30072189
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32532839
N Engl J Med. 2017 Aug 31;377(9):829-838
pubmed: 28586279
Nat Med. 2018 Sep;24(9):1441-1448
pubmed: 30082870
J Pathol. 2020 Jan;250(1):19-29
pubmed: 31471895
J Clin Oncol. 2020 May 10;38(14):1505-1517
pubmed: 32150489
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
Lancet. 2016 Apr 30;387(10030):1837-46
pubmed: 26970723
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
Nat Rev Dis Primers. 2020 May 7;6(1):38
pubmed: 32382051
Ann Oncol. 2021 Sep;32(9):1193-1194
pubmed: 34082018
Adv Sci (Weinh). 2019 Aug 19;6(19):1900721
pubmed: 31592412